Together We Invest

growth-negative

שור-טק, a fintech company, invested $20 million in Vestoo less than a year ago. Vestoo has now raised $15 million led by Standard Bank. The value of שור-טקs holding in Vestoo is now higher than the value at which שור-טק is traded on the stock exchange. שור-טקs partnership stock jumped 8% in a trading volume of 1.6 million shekels, 8 times the average volume per share, after the announcement.

growth-positive

שור-טק and יוניק-טק are joining the Tel Aviv Stock Exchange. שור-טק will invest in insurtech and fintech startups, while יוניק-טק will focus on secondary market transactions, acquiring shares from existing shareholders in startups with a valuation of $1 billion or more.

growth-positive

אבישי אברהמי, מייסד ומנכ"ל Wix, הצטרף לשותפות המו"פ יוניק-טק המתכוננת להנפקה בבורסת תל אביב. חברת ההשקעות של אברהמי, אופורטו דלתא, רכשה 1,007 מניות של השותף הכללי בשותפות המו"פ, ומחזיקה ב-6% ממניות השותף הכללי. אברהמי קיבל אופציה לרכישת 747 מניות נוספות של השותף הכללי בכפוף לרכישת 20 מיליון יחידות השתתפות של יוניק-טק לאחר ההנפקה.

growth-positive

טוגדר השקעות, an investment company, has expanded its activities in the field of biomedicine with investments in medical devices and solutions. The company has active campaigns in innovative uterine extraction analysis and an AI system for hospitals. The LAP BOX, developed by ARK Surgical, provides a safe and efficient method for uterine extraction. Profility has developed an AI system for personalized patient treatment and recovery prediction. Silenseed is developing a breakthrough cancer treatment and is currently raising funds through טוגדרs Angel Club. טוגדר presents the projects to its investment committee and, upon approval, determines the fundraising goals. The campaigns have raised significant amounts exceeding the original targets.

growth-positive

Israeli biotech company, Silenseed, has developed a targeted drug that silences the disease-causing gene in 95% of cases, unlike chemotherapy, which weakens the entire system. The drug is based on a field in biology called gene silencing. The company has received FDA approval for a comprehensive trial in the US and has set up production capabilities in Modiin according to FDA standards. The company is currently raising $3 million to complete the trial and will later raise an additional $15 million.